2025年7月和8月，Liquidia分析了为期52周的前瞻性、开放标签ASCENT研究的中期数据，该研究全面招募了54名患有间质性肺病（PH-ILD）相关肺动脉高压的患者

2025-08-12 18:36

Safety data and observed exploratory efficacy data was summarized for Week 8 and Week 16 timepoints.
The tolerability profile of YUTREPIA in PH-ILD was consistent with initial observations in the first 20 patients at Week 8. Most patients continued on treatment to Week 16 with 10 of 54 (18.5%) discontinuing the study.
There were no discontinuations stemming from drug-related adverse events, such as cough or throat irritation. Of those patients who reported a treatment related cough, 24 of 26 patients reported a mild cough and 2 patients reported a moderate cough.
The mean daytime simplified cough scores remained essentially unchanged from baseline through Week 16, suggesting the cough tended to be transient nature. Dose titration remains steady, with a median dose of 132.5 mcg QID at Week 8, and 159 mcg QID at Week 16.
The highest exposure at Week 16 was 318 mcg QID. The median improvements in six-minute walk distance were 21.5 meters at Week 8 and 31.5 meters at Week 16.
Release of detailed clinical data is targeted for medical conferences in September and October of 2025.